May 05, 2011 10:10 ET

DIAGNOS Announces Positive Impact of CARA DR (Diabetic Retinopathy) Screening on Access to Quality Care in a Quebec First Nations Community

BROSSARD, QUEBEC--(Marketwire - May 5, 2011) - DIAGNOS inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in the use of artificial intelligence and advanced knowledge-extraction techniques, announces today the result of a CARA screening project with the Kateri Memorial Hospital Center.

"We have received very positive feedback from the patients, medical, and technical personnel that took part in the project. Many patients had not had any eye exam performed in 5 yrs because of limited access to an eye healthcare professional and of the current requirement for all patients to have their eyes dilated and the number of images required as standard protocol." The results showed that if the screening is conducted, like it is done in some parts of Europe where mydriatic drops are applied only when needed, and with the use of the CARA tele-ophthalmology platform, there is a significant increase in people's willingness to return on a yearly basis. The team has found that using DIAGNOS' CARA, the DRS fundus camera, and screening process based on international best practices, to be effective, simple cost efficient, comfortable and non intrusive. "This has the potential to be an efficient and effective screening program for the people in the Kahnawake community." said Dr. Suzanne Jones. MD CM CCFP FCFP, Director of Medical Affairs

"This success has allowed us the privilege of being invited to return to the Kahnawake community to continue the initiative with Kateri Memorial Hospital. Our success in Kahnawake demonstrates the value we can help create and we look forward to offering our services to all First Nations Peoples throughout North America", said Yvan Michon, DIAGNOS' representative responsible for the initiative.

"We continue to approach communities in Canada and abroad that can benefit from convenient remote access to scarce specialists using our platform. CARA, as a tool, allows doctors who care for diabetic patients to connect with ophthalmology specialists, who now can remotely screen patients and ultimately treat those that require their expertise" said Peter Nowacki, DIAGNOS' Vice-President.

About CARA

CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA's image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras. CARA is a cost-effective tool for processing large numbers of images, in real-time and has been issued a licence by Health Canada for commercialization in Canada.

About CARA Field Trials

DIAGNOS has successfully conducted 19 field trials in the past 12 months in order to demonstrate CARA capability to target audiences and prospective clients, as well as to field test and refine our product and service offering. These trials were conducted in Canada, United States, Mexico, United Arab Emirates, Oman, and India, with future trials planned or scheduled for those countries as well as Kuwait, Bahrain, Qatar, Pakistan, Indonesia, China, Vietnam and others. The settings for these trials range from small regional health centres, to large (multi-million patients per year) hospital systems, as well as representatives of governments and health ministries. These trials form the basis for our robust sales pipeline and revenue forecast.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX VENTURE:ADK), with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare, natural resources, and entertainment.

For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

Contact Information

  • DIAGNOS Inc.
    Investor relations representative: Andre Larente
    1-877-678-8882 or 450-678-8882, ext. 224